PLASMA-PROTEIN BINDING OF LIDOCAINE AND WARFARIN IN INSULIN-DEPENDENT AND NON-INSULIN-DEPENDENT DIABETES-MELLITUS

被引:10
作者
OBYRNE, S
BARRY, MG
COLLINS, WCJ
OCONNOR, P
CULLEN, MJ
FEELY, J
机构
[1] TRINITY COLL DUBLIN,ST JAMESS HOSP,SCH MED,DEPT PHARMACOL & THERAPEUT,DUBLIN 8,IRELAND
[2] TRINITY COLL DUBLIN,ST JAMES HOSP,SCH MED,DEPT ENDOCRINOL,DUBLIN 8,IRELAND
关键词
D O I
10.2165/00003088-199324020-00007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We examined the plasma protein binding of an acidic drug (warfarin bound to albumin) and a basic drug [lidocaine (lignocaine) bound to alpha1-acid glycoprotein] in 15 patients with insulin-dependent diabetes mellitus (IDDM) and 15 matched controls. We also examined protein binding of warfarin and lidocaine in 30 patients with non-insulin-dependent diabetes (NIDDM) and 25 controls. Compared with control, the binding of both warfarin (98.81 +/- 0.02 vs 98.57 +/- 0.03%, mean +/- SEM) and of lidocaine (69 +/- 2 vs 58 +/- 2%) was significantly reduced in IDDM. This group had lower concentrations of both albumin and alpha1-acid glycoprotein (AAG), achieving statistical significance vs control for albumin only. In the patients with NIDDM, who had a similar level of glycosylated haemoglobin, while there was no significant difference in the binding of lidocaine there was a significant increase in warfarin binding compared with the control population (99.01 +/- 0.03 vs 98.82 +/- 0.04%). This study suggests that binding of both acidic and basic drugs is altered in both IDDM and NIDDM.
引用
收藏
页码:183 / 186
页数:4
相关论文
共 11 条
[1]  
DENGLER TJ, 1989, EUROPEAN J CLIN P S1, V36, pA65
[2]   PLASMA-PROTEIN CARBAMYLATION AND DECREASED ACIDIC DRUG PROTEIN-BINDING IN UREMIA [J].
ERILL, S ;
CALVO, R ;
CARLOS, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1980, 27 (05) :612-618
[3]   SERUM-PROTEIN BINDING OF PHENYTOIN AND VALPROIC ACID IN INSULIN-DEPENDENT DIABETES-MELLITUS [J].
GATTI, G ;
CREMA, F ;
ATTARDOPARRINELLO, G ;
FRATINO, P ;
AGUZZI, F ;
PERUCCA, E .
THERAPEUTIC DRUG MONITORING, 1987, 9 (04) :389-391
[4]  
Gulyassy P F, 1983, Kidney Int Suppl, V16, pS238
[5]   THE EFFECTS OF DIABETES-MELLITUS ON PHARMACOKINETICS AND PHARMACODYNAMICS IN HUMANS [J].
GWILT, PR ;
NAHHAS, RR ;
TRACEWELL, WG .
CLINICAL PHARMACOKINETICS, 1991, 20 (06) :477-490
[6]  
KEMP SF, 1987, CLIN PHARMACOL THER, V41, P170
[7]  
KREMER JMH, 1988, PHARMACOL REV, V40, P1
[8]   GLUCOSYLATED ALBUMIN AND ITS INFLUENCE ON SALICYLATE BINDING [J].
MEREISH, KA ;
ROSENBERG, H ;
COBBY, J .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1982, 71 (02) :235-238
[9]   CLINICAL PHARMACOKINETICS AND ENDOCRINE DISORDERS - THERAPEUTIC IMPLICATIONS [J].
OCONNOR, P ;
FEELY, J .
CLINICAL PHARMACOKINETICS, 1987, 13 (06) :345-364
[10]   ABNORMAL SERUM-PROTEIN BINDING OF ACIDIC DRUGS IN DIABETES-MELLITUS [J].
RUIZCABELLO, F ;
ERILL, S .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1984, 36 (05) :691-695